Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Hematology, Hematology, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 1/21/2018 |
| Start Date: | August 2012 |
| End Date: | June 2, 2016 |
Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53
The purpose of the study is to isolate and characterize stem cells of patients with
Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not
working the way they should be and why they seem to be sensitive to regulatory factors in the
blood, such as clotting.
Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not
working the way they should be and why they seem to be sensitive to regulatory factors in the
blood, such as clotting.
Specific Aim 1: Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it
affects MPN stem cell function.
Specific Aim 2. Assess the effects of a combination of low doses of IFNα and RG7112 on MPN
HSC/HPC.
affects MPN stem cell function.
Specific Aim 2. Assess the effects of a combination of low doses of IFNα and RG7112 on MPN
HSC/HPC.
Inclusion Criteria:
- polycythemia vera or essential thrombocythemia
- agree to give blood for study
Exclusion Criteria:
We found this trial at
1
site
1428 Madison Ave
New York, New York 10029
New York, New York 10029
(212) 241-6500
Principal Investigator: Ronald Hoffman, MD
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
Click here to add this to my saved trials
